Glenmark has recently launched Remogliflozin - a novel SGLT2 inhibitor- and India is the first country to get access to this innovative drug . Remogliflozin has been studied in 26 clinical trials globally , covering about 2,500 patients from various ethnicities . Phase III clinical trials are the best way to find a new paradigm for treatment and change the way how doctors treat patients. Glenmark invites you for an interactive webinar on 12th May 2019 from 11 am onwards.
In this webinar, Dr. J C Mohan and Dr. Shailaja Kale will talk about the "Indian Experience Of Remogliflozin- Phase III Clinical Study " . We invite you to submit your questions which will be answered by the speakers at the end of the session.
